Tildren® (tiludronate disodium) Reduces Bone Resorption

The primary action of Tildren® is to regulate osteoclasts in the areas of excessive activity. Following IV infusion, Tildren® travels systemically and binds to the mineral matrix of the bone. The acidity of the remodeling environment causes the release of Tildren® from the bone matrix into the resorption space. This leads to improved bone remodeling, decreased mineral loss, and alleviation of pain induced by abnormal osteolysis.


Learn More About How Tildren® Works

  1. Tildren® binds preferentially to the mineral phase of the bone at remodeling sites.
  2. Acidification breaks the bond.
  3. Tildren® is taken into the osteoclast by endocytosis.
how circles

See Tildren® at Work

In navicular syndrome, excessive mechanical stress results in bone resorption outpacing bone formation.

Tildren® (tiludronate disodium) restores balance to the process of bone remodeling by partially inhibiting bone resorption by:

  1. Modulating excessive osteoclastic activity
  2. Not modifying osteoblastic activity
  3. Slowing the rate of bone turnover

By modulating excessive osteoclastic activity, bone remodeling can normalize.

tildren at work

The Proven Effectiveness of Tildren®

The active ingredient in Tildren® is tiludronate disodium, a bisphosphonate that regulates osteoclasts in areas of excessive activity.

  1. Tildren® is administered via intravenous infusion over a 90-minute period, quickly binding to the mineral matrix of the bone.
  2. The acidity of the remodeling environment releases Tildren® from the bone matrix, where it is then taken into the osteoclast.
  3. Once inside, Tildren® inhibits the bone re-absorption process and kills off excess osteoclasts.

Safe and Long-lasting Relief

A single 500 mg vial treats horses up to 1,210 lb.

Controlled administration – Reconstituted with 0.9% sodium chloride solution and administered through intravenous infusion over the course of 90 minutes.

Safe – Limited and transient side effects when used according to label.

Long-lasting relief – A single treatment lasts up to six months.

1 Freedom of Information Summary. NADA #141-420. Approved February 13, 2014.

how graph bm

In conjunction with corrective shoeing, Tildren® has been proven to be more effective in controlling the clinical signs of navicular syndrome than corrective shoeing alone.1

Do not use in horses with impaired renal function or with a history of renal disease. NSAIDs should not be used concurrently with TILDREN®. Concurrent use of NSAIDs with TILDREN® may increase the risk of renal toxicity and acute renal failure. Horses should be observed closely for 4 hours post-infusion for the development of clinical signs consistent with colic or other adverse reactions.

Caution should be used when administering TILDREN® to horses with conditions affecting mineral or electrolyte homeostasis (e.g. HYPP, hypocalcemia) and conditions which may be exacerbated by hypocalcemia (e.g. cardiac disease). The safe use of TILDREN® has not been evaluated in horses less than 4 years of age, in pregnant or lactating mares, or in breeding horses. See package insert for full prescribing information.